Navigation Links
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
Date:1/18/2008

of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which has received approval to begin Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases. In January 2007 the Company announced a major strategic alliance with American-based Genentech, Inc. in the cardiovascular field. These projects are based on a competitive and in substance patented technology platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA.

The Company, which currently has 96 employees, is located at Ideon in Lund.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements a
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
2. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
3. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
4. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
5. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
9. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Foster City, CA (PRWEB) October 01, 2014 ... century, it leaves no room for doubt that this century ... and innovations in the field of medicine science. The fact ... health problems is not unknown to the scientific community. Almost ... and pollution and therefore can be prevented with medical care ...
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... October 1, 2014 Industry ... invited to engage around the theme, ,Commercial Opportunities in ...   Elsevier , a world-leading ... services, will host a gathering of some of the ... trends impacting healthcare today and in the future. The ...
(Date:9/30/2014)... Pacific Northwest Biotechnology, LLC - Product ... Markets Direct,s, ,Pacific Northwest Biotechnology, LLC - Product ... the Pacific Northwest Biotechnology, LLC,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Pacific ... various stages, therapeutics assessment by drug target, mechanism ...
Breaking Biology Technology:Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... 18, 2011 Ingenuity® Systems, a leading provider ... Erasmus Medical Center, jointly announced a scientific collaboration ... As part of the collaboration, Erasmus ... derive the most impactful biological insights from their ...
... German . , At the beginning of the ... for use of the first thiol-based self-assembling monolayers (SAMs). Nanotechnology ... now honored with the Research Award of the Alexander von ... of Functional Interfaces (IFG) at KIT and the Bielefeld Institute ...
... Jan. 14, 2011 Dendreon Corporation (Nasdaq: ... offering of $540 million aggregate principal amount of 2.875% ... in an offering registered under the Securities Act of ... from its previously announced $500 million offering.  The Notes ...
Cached Biology Technology:Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research 2New impulses for surface research 2Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 2Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 3Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016 4
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... your doctor to know what goes wrong with your muscles ... to know what "normal" actually is. That,s where a new ... FASEB Journal comes in. In the ... set of molecules that can help scientists "see" which genes ... more, they found never-before-detected gene activity and that men have ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... been named among the nation,s most innovative users of ... has been announced and can be viewed at ... the nation,s most innovative users of information technology and ... some of the best-known organizations in the country. Past ...
... With only two weeks to go and almost a ... 2013 have reached their final stages. This year,s conference ... Simons will deliver the opening keynote lecture and explain ... cells work. In further keynote lectures, Hans Clevers will ...
... Sept. 8, 2013 An ambitious partnership among more ... & Gamble,s (P&G,s) nonprofit program, Children,s Safe ... 6 billion quarts of clean drinking water to families ... they,re just getting started. CSDW Manager Allison Tummon ...
Cached Biology News:All set for The EMBO Meeting 2013 2Water-purification plant the size of a fast-food ketchup packet saves lives 2
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
... The CpGenome Fast DNA Modification Kit contains ... on a DNA sample. In the bisulfite ... sulfonated, converting them to uracils, while 5-methylcytosines ... treated DNA will differ depending on whether ...
... Molecular Probes EnzChek Pyrophosphate Detection ... spectrophotometric,method for measuring the inorganic pyrophosphate ... biochemical reactions, such as DNA and,RNA ... enzyme,adenylate cyclase and the enzymatic activation ...
... high PCR specificity *High PCR specificity ... enzyme with unique QIAGEN PCR Buffer ... provided by the stringent built-in hot ... Master Mix and simple reaction setup ...
Biology Products: